Keiichi Maruyama
Keiichi Maruyama publishes mostly in Pulmonary and Respiratory Medicine, Surgery and Oncology, on topics such as Gastric Cancer Management and Outcomes, Metastasis and carcinoma case studies and Gastrointestinal Tumor Research and Treatment.
- World rank
- #1,046,860 of 7,710,434 ranked researchers
- Rank in United States
- #340,326 of 1,627,098
- Works
- 109
- Citations
- 4.9k
- Citations per work
- 44.6
What does Keiichi Maruyama research?
Keiichi Maruyama's work is mostly in Medicine (92%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences10091.5%
- Medicine10091.5%
- Everything else98.5%
- 1Pulmonary and Respiratory Medicine41% of their works
- 2Surgery28% of their works
- 3Oncology10% of their works
- 4Gastroenterology9% of their works
- 5Epidemiology3% of their works
- 6Radiology, Nuclear Medicine and Imaging1% of their works
Research topics
- Gastric Cancer Management and Outcomes
- Metastasis and carcinoma case studies
- Gastrointestinal Tumor Research and Treatment
- Helicobacter pylori-related gastroenterology studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
- Pancreatic and Hepatic Oncology Research
Which keywords describe Keiichi Maruyama's research?
The keywords of their largest research topics: Gastric Cancer, Endoscopic Resection, Chemotherapy, Lymph Node Dissection, Molecular Characterization, Lung Tumors, Metastatic Carcinomas and Prognostic Factors.
- Pancreatic Cancer
- Esophageal Perforation
- Endoscopic Stenting
- Biliary Tract Cancer
- Inflammation
- Sunitinib
- Epidemiology
- Prognostic Factors
- Lung Tumors
- Lymph Node Dissection
- Endoscopic Resection
- Gastric Cancer
- Chemotherapy
- Molecular Characterization
- Metastatic Carcinomas
- Surgical Management
- Imatinib Mesylate
- Helicobacter pylori
- Neoadjuvant Therapy
- Cholangiocarcinoma
- Esophageal Carcinoma
- Preoperative Chemoradiotherapy
- Surgical Complications
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 23 words, with their numbers
- Gastric Cancer842 topics
- Endoscopic Resection752 topics
- Chemotherapy722 topics
- Lymph Node Dissection651 topic
- Molecular Characterization651 topic
- Lung Tumors331 topic
- Metastatic Carcinomas331 topic
- Prognostic Factors322 topics
- Surgical Management322 topics
- Epidemiology212 topics
- Imatinib Mesylate211 topic
- Sunitinib211 topic
- Helicobacter pylori191 topic
- Inflammation191 topic
- Neoadjuvant Therapy172 topics
- Biliary Tract Cancer111 topic
- Cholangiocarcinoma111 topic
- Endoscopic Stenting101 topic
- Esophageal Carcinoma101 topic
- Esophageal Perforation101 topic
- Preoperative Chemoradiotherapy101 topic
- Pancreatic Cancer71 topic
- Surgical Complications71 topic
Where does Keiichi Maruyama work?
Keiichi Maruyama's main affiliation in the publication record is National Cancer Center, United States.
How many publications and citations does Keiichi Maruyama have?
OpenAlex counts 109 works and 4,866 citations for Keiichi Maruyama, an h-index of 33, ranking #1,046,860 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Keiichi Maruyama. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.